WitrynaImmatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics. Home; ... Immatics N.V. … Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 … Immatics is developing targeted TCR-based immunotherapies with an emphasis on … Immatics believes that TCRs represent a new therapeutic opportunity for … Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 … Investors & Media Immatics N.V. Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 … Immatics combines the discovery of true targets for cancer immunotherapies with … The management team at Immatics consists of an interdisciplinary group … Witryna22 mar 2024 · Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany
Events & Presentations Immatics N.V.
Witryna市场头条新闻、重点公司财报、实时市场数据和深度分析文章。 Witryna17 mar 2024 · Immatics Biotechnologies GmbH Anja Heuer Corporate Communications Phone: +49 89 540415-606 [email protected] Jordan Silverstein Head of … high school football roster school football
Contact Us Immatics
WitrynaImmatics Biotechnologies GmbH. 72076 Tübingen +1 Ort. Vollzeit. You will work in Tübingen or Munich (Germany) in an interdisciplinary environment with colleagues from research, pre-clinical and clinical development ... WitrynaImmatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany. Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: [email protected]. Immatics US, Inc. 2201 W. Holcombe Blvd., Suite 205 Houston, Texas 77030. Business line: +1 346 204-5400 Fax line: +1 346 204-5931 Witryna20 lut 2024 · Tuebingen, Germany and Houston, Texas, February 20, 2024 – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to … high school football rushing leaders